Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CORIOLAN Study to analyse the performance of new imaging techniques for monitoring and determining the prognosis of patients with advanced stage colorectal cancer

Project 3

CAR-T Project (Think Clinical Trial)

Project 4

NeoRHEA Clinical Study
  • Project holder : Michael Ignatiadis
  • Collaboration(s) : Belgian Hospitals and Oncology Centres
  • Funding (or) Support : Pfizer

Project 5

MIME Clinical Study

Project 6

TP53 targeting in BRAF mutation melanoma

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid and Rare Tumours
New Innovative Treatments
Pr A. Awada
Dr Ph. Aftimos
Dr S. Aspeslagh
Dr Ch. Jungels
Dr N. Kotecki

Breast Oncology
Pr M. Piccart
Dr D. de Valeriola
Pr Ch. Sotiriou
Dr E. de Azambuja
Dr A. Gombos
Dr M. Ignatiadis
Dr F. Lebrun
Dr L. Polastro
Dr Ph. Aftimos
Dr D. t’Kint de Roodenbeke
Dr L. Buisseret

Dr L. Dal Lago

Cervico-facial Oncology  
Dr Y. Lalami

Skin Tumour Oncology                
Dr J. Kerger / Pr A. Awada
Dr M. Suppa

Digestive Oncology     
Dr A. Hendlisz
Dr A. Deleporte
Dr G. Machiels
Dr F. Puleo
Dr L. Shaza
Dr L. Polastro (with the exception of gastroenterology/endoscopy)

Gynaecological Oncology
Dr J. Kerger
Dr F. Lebrun
Dr L. Polastro
Dr D. t’Kint de Roodenbeke

Thoracic Oncology
Pr J.-P. Sculier
Pr Th. Berghmans
Pr A.-P. Meert
Dr B. Grigoriu

Urogenital Oncology
Bone and Soft Tissue Tumour Oncology
Dr Th. Gil
Dr S. Sideris
Dr N. Martínez-Chanza (urogénital)
Dr Ch. Jungels (sarcomes)

Pr M. Abramowicz
Dr D. t’Kint de Roodenbeke
Dr I. Vandernoot

Central Nervous System Oncology
Pr E. de Azambuja

Consultants :    
Pr J. Klastersky (médecine interne/oncologie)

Dr A. Covas (gastroentérologie/oncologie digestive)
Dr Z. El Ali (oncologie médicale)
Dr S. Latifyan (oncologie médicale)
Dr D. Levacq (oncologie médicale)

 Scientific publications

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Authors : Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP
Year : 2019
Journal : Acta Clin Belg
Pages : 1-8

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Year : 2019
Journal : J Clin Oncol
Pages : JCO1801010

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors : Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B
Year : 2019
Journal : Ann Oncol

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, Von Minckwitz G, Baselga J
Year : 2019
Journal : Ann Oncol

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more